Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) vs Zoetis Inc (ZTS) Price & Performance

iShares S&P GSCI Commodity-Indexed Trust ETFTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

iShares S&P GSCI Commodity-Indexed Trust ETF vs Zoetis Inc — how do they compare? iShares S&P GSCI Commodity-Indexed Trust ETF trades at $30.94, while Zoetis Inc trades at $76.88 (market cap $31.25B). The key difference: Zoetis Inc pays a 2.84% dividend while iShares S&P GSCI Commodity-Indexed Trust ETF pays none, and iShares S&P GSCI Commodity-Indexed Trust ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.

GSGZTS
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$34.77$156.76
52-Week Low
$22.06$71.91
Market Cap
$31.25B
Enterprise Value
$38.54B
Dividend Yield
2.84%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares S&P GSCI Commodity-Indexed Trust ETF

GSG trades at $31.00, up 1.57% today, with strong bullish technical signals from moving averages and ADX indicators, though RSI levels suggest overbought conditions. The stock's support and resistance levels are consolidated at $31.00, indicating a pivotal price point. Recent news highlights commodities as a key market theme, which may benefit GSG given its focus.

The outlook for GSG is cautiously optimistic, driven by bullish technical trends and positive sentiment around commodities. Risks include potential overbought corrections and reliance on commodity market stability. Investment opportunities hinge on sustained commodity demand, but investors should monitor earnings fundamentals for validation.

Zoetis Inc

ZTS trades at $74.08, down 1.74% on the day, with a bearish technical signal from moving averages. The company reported strong 2025 results including $9.47B revenue, $2.67B net income, and a 28.03% net margin, but missed Q1 2026 EPS estimates. Recent news highlights a securities class action lawsuit and the launch of Lenivia in Canada and the EU.

Despite near-term legal overhangs and a recent earnings miss, ZTS maintains robust profitability and a consensus price target of $101.43 implies significant upside. Key risks include litigation outcomes and competitive pressures in the companion animal segment, while solid cash flow and high ROE support long-term value.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares S&P GSCI Commodity-Indexed Trust ETF

GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.

Read more on GSG

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS